Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty

benzinga.com/general/biotech/25/05/45655674/rocket-pharmas-gene-therapy-future-clouded-by-regulatory-uncertainty

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) on Tuesday announced an update related to RP-A501, its investigational gene therapy for Danon disease, a rare X-linked dominant genetic disorder that manifests with the clinical triad of cardiomyopathy (stiff heart muscles), skeletal myopathy…

This story appeared on benzinga.com, 2025-05-28 19:35:36.
The Entire Business World on a Single Page. Free to Use →